M elanoma is a rare subtype of skin cancer that arises from melanocytes, the specialized pigment cells that synthesize melanins and are responsible for skin color. Approximately 212,000 new cases of melanoma are diagnosed annually worldwide, resulting in 65,000 melanoma-related deaths (1) . Although not as common as other subtypes of cutaneous carcinomas, melanoma is the most dangerous form, accounting for 75% of skin cancer deaths (http:// www.aafp.org/afp/20000715/357.html, OMIM 155600). When diagnosed early, more than 80% of cases can be successfully treated through surgical resection. However, metastatic malignant melanoma is resistant to currently available treatments and carries a very poor prognosis with a less than 10% 5-year survival rate (2) (3) (4) . Ras/Raf and PI3K/Akt signaling have been implicated in melanoma development; however, the exact mechanism(s) of melanocyte transformation, disease progression, and development of chemoresistance are still not well understood.
As a master transcription factor in melanocytes, microphthalmia-associated transcription factor (MITF) controls the expression of genes important for melanocyte development, function and survival (5) . Alpha-melanocyte stimulating hormone (MSH) activates melanocortin-1 receptor (MC1R), resulting in a cAMPmediated phosphorylation/activation of the CREB/ATF family of transcription factors, induces MITF expression, and regulates pigmentation in melanocytes. The MITF locus contains several distinct promoters and alternative transcription initiation sites that generate multiple isoforms of MITF, which differ in their amino-termini and expression patterns (Fig. S1 ). Among them MITF-A and MITF-H are most abundant and widely expressed in many cell types; MITF-E is expressed abundantly in cultured mast cells (6) ; and MITF-M is predominantly expressed in melanocytes and pigmented melanoma cells. The differential expression of MITF isoforms in a variety of tissues suggests that other mechanisms may affect their expression in addition to MSH signaling. For example, a variety of signaling cascades, including Wnt (7) , and more specifically transcription factors such as LEF-1, CREB, SOX10, and PAX3 have been demonstrated to bind the MITF-M promoter and regulate its expression (8, 9) . Recent genomic analyses have shown that the MITF locus is amplified in melanoma cells (Ϸ10% of cutaneous tumors and 15-20% of metastatic tumors) and that MITF can function as a lineage-survival oncogene (10, 11) . Expression of MITF-M is also deregulated in clear cell sarcoma (CCS), driving CCS cell survival and tumor growth (12) .
To further clarify the biological role of MITF-M and to identify additional regulators of MITF-M expression, we performed a genome-wide gain-of-function cDNA screen with a MITF-M promoter reporter assay. TYRO3 was identified as a positive regulator of MITF-M transcription in melanoma cells. Increased expression of TYRO3 was detected in established melanoma cancer cell lines, as well as primary tumor samples. Overexpression of TYRO3 overcomes BRAF(V600E)-induced senescence in melanocytes, whereas knockdown of TYRO3 inhibits melanoma cell proliferation, sensitizes them to chemotherapeutic agents in vitro, and inhibits tumorigenesis in vivo. These data suggest that targeting TYRO3 with small molecules or antibodies may potentially be useful for the treatment of melanoma. In an effort to identify upstream factors regulating Mitf-M transcription, we performed a genome-wide gain-of-function cDNA screen using a Mitf-M promoter driven luciferase reporter gene as a readout (13) . The Mammalian Gene Collection (MGC) consisting of approximately 16,000 cDNAs was screened by co-transfection of reporter plasmids and cDNA expressing plasmids into B16-F0 mouse melanoma cells using a 384-well, high-throughput screening format. The average fold activation (afa) value, calculated for each gene based on the signal strength in two independent experiments, was used for hit selection. Using afa Ͼ3.0 as the cutoff point, 263 hits were selected from the primary screen. To filter out false positives that nonspecifically activate luciferase activity, a counter screen was performed using a group of reporter constructs driven by alternative promoter sequences, including Mitf-A, Mitf-H, and cAMP-responsive element (CRE). Using an afa Ͼ3.0 for the Mitf-M reporter and an afa Ͻ3.0 for all other reporters as a selection criteria, 23 genes were chosen for further follow-up as positive regulators of Mitf-M reporter expression in melanoma cells. To confirm their function in wild-type melanoma cells, plasmids containing these cDNAs were transfected into B16-F0 cells and mRNA levels of mouse Mitf-M were analyzed using quantitative reverse-transcription PCR (qRT-PCR, Fig. 1A ; see the gene list in Table S1 ). Among these 23 genes, 15 genes significantly increased Mitf-M transcription as compared to the empty vector control. A number of these genes have been associated with cancers previously, including retinoic acid receptor, RARa [translocation mutation in acute promyelocytic leukemia, (14) ], and receptor tyrosine kinase, Tyro3 [overexpressed in mouse mammary tumors (15) ].
Analysis of the tissue and cell line specific expression of the selected 15 genes revealed elevated levels of TYRO3 in human melanoma cell lines [GNF SymAtlas, http://symatlas.gnf.org/ SymAtlas/ (16)] but not in other human cancer lines across the NCI60 panel. Furthermore, we detected increased expression of TYRO3 in primary human melanoma samples at different stages compared to normal skin tissues using real time quantitative RT-PCR (Fig. 1B) . Twenty out of 40 melanoma tissue samples showed increased TYRO3 mRNA levels (over 3-fold) compared to normal skin tissues, although there was no obvious correlation between TYRO3 mRNA levels and tumor stage. TYRO3 expression correlated well with elevated expression levels of MITF-M in these samples (Fig. S2 ) as well. Neither AXL nor MER, the other two members of the TYRO3/AXL/MER (TAM) receptor protein-tyrosine kinase family, is differentially expressed between melanoma tumor samples and normal skin tissues (Fig.  S2) . These results suggest that TYRO3 may play an important role in melanoma etiology. Other genes from the screen do not show significant overexpression in melanoma cell lines, and therefore, we focused our further follow-up studies on TYRO3. As a member of the TAM receptor family, TYRO3 has been implicated in the regulation of the immune system (17), including natural killer cell differentiation (18) , and macrophage and neutrophil functions (19) . The TAM family receptor kinases are also involved in cell proliferation, survival and transformation in a variety of cellular systems (20) (21) (22) , and play important roles in different types of cancer (23) (24) (25) .
TYRO3 Regulates MITF-M Transcription Through the Control of SOX10
Nuclear Localization. MITF-M expression is controlled by the CREB, PAX3, and SOX10 transcription factors (8, 9) . To determine whether TYRO3 affects the activation of established MITF-M regulators, we analyzed the effects of TYRO3 on the nuclear protein levels of CREB, PAX3, and SOX10 when overexpressed in B16-F0 cells. Concomitant with an increase in TYRO3 and MITF-M expression, we observed an increase in SOX10 nuclear localization, whereas nuclear protein levels of CREB or PAX3 were not affected ( Fig. 2A) . To verify the role of SOX10 in mediating MITF-M transcription downstream of TYRO3, we knocked down Sox10 expression in B16-F0 cells using gene-specific siRNAs (Dharmacon). As expected, Sox10 knockdown diminished Tyro3 overexpression induced Mitf-M reporter activation (Fig. 2B) . Knockdown of Sox10 also slightly decreased the reporter signal in empty vector transfected cells, consistent with the fact that endogenous SOX10 contributes partially to Mitf-M expression in these cells. RT-PCR analysis of Mitf-M mRNA levels in wild-type B16-F0 cells gave similar results (Fig. S3) .
To determine whether human TYRO3 overexpression is sufficient to drive the ligand-independent activation of downstream cell signaling, we ectopically expressed wild-type (WT) TYRO3 and its kinase-dead (KD) mutant (lysine 550 in the conserved ATP-binding site, which is analogous to lysine 614 of MER (26) was replaced by alanine, K550A) in 293T cells. TYRO3 overexpression increased the overall level of tyrosine phosphorylation in the whole cell lysate (Fig. 2C) , indicating hyperactivation of the downstream signaling components, which is consistent with previous findings that Src/Fyn/Yes family kinases and PI3K can be recruited and phosphorylated by TYRO3 upon activation/ autophosphorylation (27, 28) . The kinase-dead mutant form of TYRO3 failed to elevate phospho-tyrosine levels, confirming the requirement for kinase activity in cell signaling.
To further investigate the effect of TYRO3 on SOX10 localization, we co-transfected wild-type and kinase-dead TYRO3, and Flag-tagged SOX10 into 293T cells. Assessment of nuclear Flag-SOX10 level by Western blot using an anti-Flag antibody indicated that the levels of nuclear SOX10 increased upon wild-type TYRO3 overexpression, as compared to the control cells (Fig. 2D) . Overexpression of the kinase-dead mutant did not enhance SOX10 nuclear localization, consistent with the absence of increased phospho-tyrosine levels. In addition, the kinase-dead mutant failed to activate the MITF-M reporter gene as well (Fig. 2E) , again indicating that the effects of TYRO3 are dependent on its kinase activity. However, the kinase dead mutant of TYRO3 does not function as a ''dominant negative'' by competing with the wild-type receptor and further inhibiting the basal level of signaling, suggesting that the basal level of SOX10 translocation and MITF expression might be regulated by other mechanisms. To confirm this mechanism in human melanoma cells, we performed shRNA-mediated TYRO3 knockdown in A2058 and MDA-MB-435 melanoma cells. Knockdown of TYRO3 decreased nuclear SOX10 levels without affecting overall protein levels (Fig. 2F ) or affecting SOX10 transcription (Fig. S4 ). These experiments demonstrate that TYRO3 acts upstream of SOX10 to regulate its nuclear localization and provide a link between TYRO3 and MITF-M through SOX10 activation.
To further explore the function of TYRO3 in melanoma cells, we performed gene expression analysis in A2058 and MDA-MB-435 melanoma cells upon TYRO3 knockdown. Genes whose expression levels changed more than 2-fold by TYRO3 knockdown were subjected to pathway analysis using Ingenuity Pathway Analysis software. The pathways affected by TYRO3 knockdown were similar for two different shRNAs and two different melanoma cell lines (Fig. S5A) . Pathway analysis revealed that TYRO3 knockdown has effects on a wide range of signaling pathways ( Fig. S5B and Tables S2 and S3), including PI3K/AKT signaling, Wnt/␤-Catenin signaling, ERK/MAPK signaling, SPAK/JNK signaling, JAK/Stat signaling, TGF-␤ signaling, and RAR activation, to name a few. Interestingly, RARa, PIK3c3, and GPR114 were identified as hits from the genomic screen, indicating potential crosstalk and involvement of these signaling pathways in melanoma. Furthermore, genes whose expression is affected by TYRO3 knockdown are involved in a wide range of cellular processes, including proliferation, survival, transformation, growth, apoptosis, and senescence, suggesting possible roles for TYRO3 in these processes.
TYRO3 Is Involved in Melanoma Cell
Proliferation and Survival. Members of TAM protein kinase receptor family are known to play a role in cell survival and protection against apoptosis (22, 29, 30) . To further address the biological function of TYRO3 in melanoma, we analyzed its role in proliferation and apoptosis in different melanoma cell lines using RNAi-mediated gene silencing. Lentiviral particles carrying scrambled control or TYRO3 targeting shRNA sequences were used to induce stable TYRO3 knockdown in melanoma cell lines. Three out of five shRNA sequences demonstrated 60-80% knockdown efficiency at both the protein and mRNA levels, and two of those constructs were used for subsequent functional studies (Figs. 2F and 3A) .
First, we analyzed the effect of TYRO3 knockdown on melanoma cell proliferation in vitro. TYRO3 knockdown significantly reduced the proliferation rates of A2058 melanoma cells (Fig. 3B) ; both shRNA constructs decreased melanoma cell proliferation to a similar extent (Ϸ10% of the control shRNA), indicating that TYRO3 plays an important role in the regulation of cell proliferation. Next, we examined whether TYRO3 mediates chemoresistance in melanomas, similar to its downstream effector MITF (10) . The effect of TYRO3 knockdown on caspase activation was determined in the presence of chemotherapeutic agents commonly used for the treatment of melanoma. TYRO3 knockdown alone induced low levels of caspase 3 activity in A2058 cells as compared to scrambled shRNA infected cells. When TYRO3 knockdown was coupled with cisplatin (10 M) or docetaxel (50 nM) treatment, a significant increase (5-fold for cisplatin and approximately 2-to 3-fold for docetaxel, respectively) in caspase activity was observed (Fig. 3 C and D) . Interestingly, no synergistic effect with temozolomide (TMZ, 50 M) treatment was observed. Consistent with the above results, cells treated with cisplatin showed increased TUNEL staining with TYRO3 knockdown compared to control shRNA (Fig. 3E) . These experiments indicate that TYRO3 knockdown sensitizes melanoma cells to chemotherapeutic agents in a manner consistent with MITF's protective role against apoptosis (31, 32) . They also provide further support for the interaction of the TYRO3 and MITF signaling cascades in melanoma, and suggest that TYRO3 may be a therapeutic target for melanoma treatment in combination with other chemotherapeutic agents.
TYRO3 Overexpression Bypasses BRAF(V600E)-Induced Senescence in
Melanocytes. Melanoma arises from melanocytes under the influence of transforming stimuli, such as activating mutations of BRAF and repression of p16 INK4a expression (33) . The BRAF(V600E) mutation has been widely found in melanoma. However, it is insufficient to transform primary melanocytes by itself, and rather induces senescence in the absence of additional oncogenic stimuli. Synergistic oncogenic mutations or silencing of tumor suppressors, such as upregulation of MITF (10) or downregulation of IGFBP7 (34) , are required to facilitate melanocyte transformation and melanoma development.
Tyro3 overexpression is able to transform 3T3 and Rat-2 fibroblasts in a ligand-independent manner in vitro (27, 35) . To address whether TYRO3 is involved in melanocyte transformation, we overexpressed TYRO3 together with BRAF(V600E) in early passage of human primary melanocytes using retroviral particles (Fig.  3F) . Expression of TYRO3 alone did not have clear effect compared to control virus infected melanocytes. Expression of BRAF(V600E) induced senescence in melanocytes and led to an increase in the percentage of senescent cells with the characteristic enlarged cell body and positive staining of senescence-associated ␤-galactosidase (SA-␤-Gal) activity (Fig. 3 G and H) . However, when TYRO3 was co-expressed with the BRAF(V600E) mutant, primary melanocytes formed colonies in which non-senescent cells dominate the population, as indicated by a strong reduction in the percentage of SA-␤-Gal positive cells. These results indicate that TYRO3 overexpression can bypass the BRAF(V600E) mutant induced senescence in melanocytes, and thus may play a role in melanoma development.
TYRO3 Knockdown Reduces the Tumorigenic Potential of Melanoma
Cells In Vivo. Melanoma cells are capable of forming xenograft tumors when injected into mice. To test the effect of TYRO3 on tumor formation by melanoma cells, we performed tumorigenesis assays with cells in which TYRO3 levels were knocked down with shRNAs. First, we examined the colony forming ability of melanoma cells upon TYRO3 knockdown under low-density or non-adherent conditions in vitro. When plated at low density (200 cells per well of 6-well plates), melanoma cells form colonies in 2-3 weeks. We observed a substantial decrease in the number of colonies (10 -15% of the control shRNA expressing cells) formed by A2058 cells stably expressing the TYRO3 shRNAs relative to scrambled shRNA infected cells (Fig. 4 A and B) . This decrease correlated with the knockdown efficiency of the shRNA sequences. In addition to inhibiting adhesion-dependent colony formation, TYRO3 knockdown significantly decreased the number of colonies formed under adhesion-independent soft-agar conditions (Fig.  4C) .
To address the role of TYRO3 in tumorigenesis of melanoma cells in vivo, we injected the TYRO3 knockdown A2058 melanoma cells into nude mice intradermally and monitored tumor initiation and growth. As expected, cells infected with nontargeting shRNA control formed detectable tumors after 12-15 days post implantation, and the tumors grew at a fast pace and started bleeding at day 30 (Fig. 4 D and E) . In contrast, the cells with TYRO3 knockdown did not form any detectable tumor by day 30. At day 52, two out of five mice had detectable tumors (Ϸ3 mm 3 ) from melanoma cells infected with shRNA1 targeting TYRO3, and one out of five mice had a detectable tumor from melanoma cells infected with shRNA2 targeting TYRO3. These experiments demonstrate that TYRO3 regulates tumor initiation and growth in vivo.
Discussion
Melanoma is an extremely aggressive disease with high metastatic potential and strong resistance to conventional chemotherapeutics. The transcription factor MITF has been identified as a ''master regulator'' of melanocytes and as a ''lineage addiction'' oncogene in malignant melanoma (36) . Consequently, the identification of upstream regulators of MITF-M expression may reveal potential therapeutic targets for metastatic chemorefractory melanoma. In this study, we identified the receptor tyrosine kinase TYRO3 as a positive regulator of MITF-M expression in melanoma cells by a genome-wide gainof-function cDNA screen. The expression levels of TYRO3 are elevated in both melanoma cells and primary melanoma samples compared to other cell lines and normal tissues. Overexpression of TYRO3 induces its autophosphorylation and activation of downstream signaling (28, 37) . We also demonstrate that TY-RO3 regulates MITF-M expression by controlling SOX10 nuclear localization, and such effects are dependent on its kinase activity. SOX10 is a transcription factor that plays a critical role in neural crest development (38) and is highly expressed in primary melanocytes and melanoma cells. We are currently investigating whether SOX10 is phosphorylated by TYRO3 or downstream signaling events, and whether such events enhance SOX10 nuclear localization. TYRO3 and other members of the TAM tyrosine kinase receptor family regulate a variety of signaling cascades involved in cellular proliferation and transformation (35, 39, 40) , as well as anti-apoptotic and survival mechanisms in cancers (24, 25, 41) . TYRO3 knockdown inhibits melanoma colony formation under adherent and non-adherent conditions, suggesting that TYRO3 may play a role in metastatic melanoma survival and contribute to its dissemination. In addition, TYRO3 knockdown sensitized melanoma cells to cisplatin and docetaxel chemotherapy-induced apoptosis, suggesting that TYRO3 signaling is important in the development of chemoresistance and has anti-apoptotic effects in cancer cells. It remains to be determined if this chemosensitization is due to the inactivation of downstream anti-apoptotic signaling pathways such as PI3K/Akt, repression of anti-apoptotic factors such as MITF-M and BCL2, or the re-activation of the BRAF (V600E)-driven senescence pathway.
The valine to glutamic acid substitution in BRAF(V600E) is found in 50% to 70% of melanomas (42, 43) . However, this BRAF mutation alone is not sufficient to transform melanocytes, but rather induces senescence, despite hyperactivated ERK signaling and activation of cellular proliferation pathways. Acquisition of additional ''driving'' oncogenic events is required to evade BRAF(V600E)-induced senescence and mediate transformation. For example, downregulation of IGFBP7 (34) and c-Myc overexpression (44) cooperate with activated BRAF to transform melanocytes. Hyperactivated ERK signaling has been shown to target MITF for degradation (45, 46) , suggesting that reduced levels of the melanocyte ''master regulator'' may play a role in BRAF-induced senescence. Mechanisms that restore MITF expression may therefore contribute to melanocyte transformation. Here we show that TYRO3 is a regulator of MITF expression and that elevated levels of TYRO3 in primary melanocytes can bypass oncogenic BRAF(V600E) mutantinduced senescence. Tyro3 overexpression is capable of transforming 3T3 fibroblasts in part through the activation of the PI3K pathway (27) . The combinatorial effect of TYRO3 mediated induction of MITF expression and PI3K/Akt pathway activation may provide the necessary survival signals to overcome BRAF(V600E)-induced senescence and drive melanoma development.
Growth arrest-specific gene 6 (GAS6), a vitamin K-dependent protein, is a well-studied ligand of the TYRO3/AXL/MER family receptors, capable of binding to and activating TYRO3 to regulate cell cycle, survival, and apoptosis (30, (47) (48) (49) (50) (51) . Concomitant expression of GAS6 and TAM receptors have been discovered in certain cancers, including breast cancer (52) and glioma (24, 39) . The role of Protein S, a close relative of GAS6, as a TYRO3 ligand is less clear: human Protein S binds to and activates murine TYRO3 in vitro (53) , bovine Protein S activates human TYRO3 (54, 55) , but human Protein S is not able to activate human TYRO3 (56) . Neither GAS6 nor Protein S has yet been shown to be connected to melanoma. Moreover, TAM family receptors are capable of autophosphorylation and ligandindependent self-activation with elevated expression, which may also be involved in tumorigenesis (37, 57) . Clearly, further investigation of the roles of GAS6 and Protein S in melanoma relative to TYRO3 activation is merited.
Finally, we have shown that TYRO3 knockdown in aggressive melanoma cells significantly reduces the in vivo tumorigenic potential in both intradermal and s.c. (Fig. S6 ) xenograft models in nude mice, which is consistent with the effects of TYRO3 knockdown on melanoma cells in vitro. In summary, these data indicate that TYRO3 overexpression is a driving oncogenic event in melanoma, and support efforts to pursue development of small molecule or antibody kinase inhibitors as a therapeutic approach for malignant melanoma.
Methods
Cell Culture. Melanoma cell line MDA-MB-435 was propagated in DMEM/F12 (Invitrogen) medium supplemented with non-essential amino acids (Invitrogen), and 10% FBS (Invitrogen). A2058 and B16-F0 cells were purchased from ATCC and cultured under the recommended conditions. 293T (ATCC) and GP2 cells were grown in DMEM (Invitrogen) supplemented with 10% FBS. Human primary melanocytes were purchased from Invitrogen, and grown in 254 medium supplemented with melanocyte growth supplements (Invitrogen).
High-Throughput Genomic Screening. cDNA library in pCMV-sport6 expression plasmids were co-transfected with reporter plasmids using Lipofectamine transfection reagent. Cells were grown for 48 h in a 37°C, 5% CO 2 incubator, firefly luciferase activity was detected using the Bright-Glo luciferase substrate (Promega).
Cell Proliferation Assay. Cells were seeded at a density of 1 million cells per 10-cm dish. Cells were trypsinized and cell number and viability were assessed by trypan blue exclusion staining at day 2, 4, 6, 8, and 10 post cell seeding using ViCell system (Beckman Coulter).
Apoptosis Assay. Cells were treated with cisplatin, temozolomide, or docetaxel for 24 h, caspase 3/7 activity was determined using Caspase 3/7 Glo Assay (Promega). Activated Caspase 3 was immunostained with anti-cleaved Caspase 3 antibody (Cell Signaling), as well. TUNEL staining was performed 48 h post-treatment using In Situ Cell Death Detection Kit (Roche) following the manufacturer's instructions.
Colony Formation Assay. Colony formation assays were carried out as previously described (59) . Briefly, 200 cells were plated into each well of 6-well plate, and cells were grown for 2-3 weeks until colonies became visible. The colonies were visualized by Crystal Violet staining. Senescent Cell Staining. Primary melanocytes were infected with V600E BRAF and TYRO3 and stained for senescence-associated ␤-galactosidase (SA-␤-Gal) activity on day 14 post infection with the senescent cell staining kit (BioVision) following the manufacturer's protocol.
In Vivo Tumorigenic Assay. Cells were trypsinized and resuspended in serum free DMEM. One million cells in a volume of 50 L were injected into each nude mouse intradermally. Tumor sizes were measured once every 3 days, the volume was calculated as length ϫ width ϫ height.
Statistical Analysis. Statistical analyses were performed using Microsoft Excel. Student's t test (two-tailed) was performed to determine significance when comparing data from different treatment groups. P Ͻ 0.05 was considered to represent significant difference.
SI.
Detailed experimental procedures can be found in SI Test .
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